Disseminated intravascular coagulation and purpura fulminans secondary to infection

Bailliere's Best Practice and Research in Clinical Haematology

Volumn 13, Issue 2, 2000, Pages 179-197

  Faust, Saul N ^a   Heyderman, Robert S ^b   Levin, Michael ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Antithrombin (ATIII); Clinical trials; Disseminated intravascular coagulation (DIC); Gram negative; Meningococcal; Pathophysiology; Protein C (PC) activated protein C (APC); Purpura fulminans; Therapy; Thrombomodulin (TM); Tissue factor (TF); Tissue factor pathway inhibitor (TFPI); Tissue plasminogen activator (tPA)

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTIPLASMIN; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 9A; COLLAGEN; CYCLIC AMP; FIBRIN; FIBRINOGEN; GLYCOSAMINOGLYCAN; HEPARIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; LOW MOLECULAR WEIGHT HEPARIN; LYSOZYME; PLASMIN; PROSTACYCLIN; PROTEIN C; PROTEIN KINASE C; RECOMBINANT THROMBOMODULIN; SEROTONIN; THROMBIN; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR RECEPTOR; THROMBOPLASTIN; THROMBOXANE A2; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOTTING; BLOOD COMPONENT THERAPY; CHILD; CLINICAL TRIAL; COMPARTMENT SYNDROME; CRYOPRECIPITATE; CYTOKINE PRODUCTION; DISSEMINATED INTRAVASCULAR CLOTTING; DOUBLE BLIND PROCEDURE; FASCIOTOMY; FIBRINOLYSIS; FULMINATING PURPURA; GANGRENE; GRAM NEGATIVE INFECTION; HEMOFILTRATION; HEMOSTASIS; HUMAN; MENINGOCOCCOSIS; NONHUMAN; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SEPTIC SHOCK; SEPTICEMIA; THROMBOCYTE AGGREGATION; THROMBOCYTE TRANSFUSION; THROMBOGENESIS; TREATMENT PLANNING; VASCULAR ENDOTHELIUM; VITAMIN INTAKE;

EID: 0033677102     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.2000.0067     Document Type: Article

References (142)

1. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies
2. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock
3. Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy
4. Blood coagulation
5. The protein C pathway: New insights
6. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex
7. A critical role for monocytes and CD14 in endotoxin-induced endothelial cell activation
8. Lipopolysaccharide recognition, CD14, and lipopolysaccharide receptors
9. Transcriptional regulation of tissue factor expression in human endothelial cells
10. Inflammatory mediators and their influence on haemostasis
11. The proinflammatory cytokine response to coagulation and endotoxin in whole blood
12. Endothelial adhesion molecule expression and its inhibition by recombinant bactericidal/permeability-increasing protein are influenced by the capsulation and lipooligosaccharide structure of Neisseria meningitidis
13. Cytokine regulation of cellular adhesion molecule expression in inflammation
14. A juxtacrine mechanism for neutrophil adhesion on platelets involves platelet-activating factor and a selectin-dependent activation process
15. Platelet/polymorphonuclear leukocyte interaction in dynamic conditions: Evidence of adhesion cascade and cross talk between P-selectin and the beta 2 integrin CD11b/CD18
16. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets
17. P-selectin induces the expression of tissue factor on monocytes
18. Anti-L-selectin antibody treatment of hemorrhagic-traumatic shock in baboons
19. Antibody to E- and L-selectin does not prevent lung injury or mortality in septic baboons
20. Administration of an antibody to E-selectin in patients with septic shock
21. Neutrophil response to Neisseria meningitidis: Inhibition of adhesion molecule expression and phagocytosis by recombinant bactericidal/permeability-increasing protein (rBP121)
22. New discoveries with mice mutant in endothelial and platelet selectins
23. Induction of human endothelial tissue factor expression by Neisseria meningitidis; the influence of bacterial killing and adherence to the endothelium
24. The influence of capsulation and lipooligosaccharide structure on neutrophil adhesion molecule expression and endothelial injury by Neisseria meningitidis
25. Cytotoxicity of activated monocytes on endothelial cells
26. Endothelial cell determinants of susceptibility to neutrophil-mediated killing
27. Alteration in glycosaminoglycan metabolism and surface charge on human umbilical vein endothelial cells induced by cytokines, endotoxin and neutrophils
28. Reduction of the anticoagulant activity of glycosaminoglycans on the surface of the vascular endothelium by endotoxin and neutrophils: Evaluation by an amidolytic assay
29. Anticoagulantly active heparin-like molecules from vascular tissue
30. Thrombomodulin structure and function
31. Biochemistry and physiology of blood coagulation
32. Thrombocytopenia in sepsis: A predictor of mortality in the intensive care unit
33. Meningococcal septic shock in children; clinical and laboratory features, outcome, and development of a prognostic score
34. Platelet factor 4 (PF4) in septicaemia
35. Plasma beta-thromboglobulin in severe infection
36. Streptococcus pneumoniae anchor to activated human cells by the receptor for platelet-activating factor
37. Platelet activation and interaction with leucocytes in patients with sepsis or multiple organ failure
38. Circulating platelet-neutrophil complexes represent a subpopulation of activated neutrophils primed for adhesion, phagocytosis and intracellular killing
39. Activated platelets express IL-I activity
40. Molecular cloning of the cDNA for tissue factor, the cellular receptor for the initiation of the coagulation protease cascade
41. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis
42. Disseminated intravascular coagulation in rabbits induced by administration of endotoxin or tissue factor: Effect of anti-tissue factor antibodies and measurement of plasma extrinsic pathway inhibitor activity
43. The structural basis of function of the TF. VIIa complex in the cellular initiation of coagulation
44. Interleukin I (IL-I) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells
45. Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin
46. Regulation of the tissue factor gene
47. Tumor necrosis factor induces tissue factor-like activity in human leukemia cell line U937 and peripheral blood monocytes
48. Induction of tissue factor on monocytes by adhesion to endothelial cells
49. Lymphocyte adhesion to human endothelial cells induces tissue factor expression via a juxtacrine pathway
50. Regulation of the tissue factor gene
51. Lipopolysaccharide induction of tissue factor expression in rabbits
52. Expression of tissue factor, thrombomodulin, and E-selectin in baboons with lethal Escherichia coli sepsis
53. In situ detection of tissue factor in vascular endothelial cells: Correlation with the malignant phenotype of human breast disease
54. Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation
55. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: Related to an unfavourable prognosis
56. Monocyte tissue factor induction by lipopolysaccharide (LPS): Dependence of LPS-binding protein and CD14, and inhibition by a recombinant fragment of bactericidal/permeability-increasing protein
57. Lethal E. Coli septic shock is prevented by blocking tissue factor with monoclonal antibody
58. Cooperative activation of human factor IX by the human extrinsic pathway of blood coagulation
59. Inflammation, sepsis, and coagulation
60. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: Evidence that endothelium is the principal site of its synthesis
61. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples
62. Tissue factor pathway inhibitor in endothelial cells colocalizes with glycolipid microdomains/caveolae. Regulatory mechanism(s) of the anticoagulant properties of the endothelium
63. Role of heparin sulfate proteoglycans in the uptake and degradation of tissue factor pathway inhibitor-coagulation factor Xa complexes
64. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: Insight into its possible mechanism of action
65. Inhibition of factor VIIa/tissue factor-induced blood coagulation: With particular emphasis upon a factor Xa-dependent inhibitory mechanism
66. Inhibitor of the extrinsic pathway of coagulation and cytokines in patients with sepsis
67. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock
68. Anticoagulantly active heparin-like molecules
69. Transient kinetics of heparin-catalyzed protease inactivation by antithrombin III. Linkage of protease-inhibitor-heparin interactions in the reaction with thrombin
70. Meningococcemia and purpura fulminans in adults: Acute deficiencies of proteins C and S and early treatment with antithrombin III concentrates
71. Protein C, protein S and C4b-binding protein in severe infection and septic shock
72. Substitution therapy with an antithrombin III concentrate in shock and DIC
73. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate
74. Postinfectious purpura fulminans caused by an autoantibody directed against protein S
75. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon
76. Protein C and protein S levels in two patients with acquired purpura fulminans
77. Protein S and C alterations in acutely ill patients
78. The quantitative association of plasma endotoxin, anti-thrombin, protein C, extrinsic pathway inhibitor and fibrinopeptide A in systemic meningococcal disease
79. Age-related differences in outcome and severity of DIC in children with septic shock and purpura
80. Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface
81. Reconstitution of the human endothelial cell protein C receptor with thrombomodulin in phosphatidylcholine vesicles enhances protein C activation
82. Modulation of glycosaminoglycan addition in naturally expressed and recombinant human thrombomodulin
83. Relationship between anticoagulant activities and polyanionic properties of rabbit thrombomodulin
84. Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor
85. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro
86. Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells
87. Identification of functional endothelial protein C receptor in human plasma
88. Plasma levels of endothelial cell protein C receptor are elevated in patients with sepsis and systemic lupus erythematosus: Lack of correlation with thrombomodulin suggests involvement of different pathological processes
89. Thrombin regulates tissue factor and thrombomodulin mRNA levels and activities in human saphenous vein endothelial cells by distinct mechanisms
90. Endothelial protein C receptor
91. Nucleotide structure and characterization of the murine gene encoding the endothelial cell protein C receptor
92. Inhibitory mechanism of the protein C pathway on tissue factor-induced thrombin generation. Synergistic effect in combination with tissue factor pathway inhibitor
93. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis
94. Fibrinolysis and the contact system: A role for factor XI in the down-regulation of fibrinolysis
95. The plasminogen (fibrinolytic) system
96. The molecular basis of fibrinolysis
97. Alterations in coagulation and fibrinolysis during sepsis
98. Changes in plasma levels of tissue-plasminogen activator/inhibitor complex and active plasminogen activator inhibitor in patients with disseminated intravascular coagulation
99. Plasminogen activator inhibitor activity in bacterial infection
100. A pathological role of increased expression of plasminogen activator inhibitor-1 in human or animal disorders
101. Types 1 and 2 plasminogen activator inhibitor and tumor necrosis factor alpha in patients with sepsis
102. Inhibitors of plasminogen activator in neutrophils and mononuclear cells from septic patients
103. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation
104. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-I gene and outcome of meningococcal disease
105. Host genetics and infectious disease
106. Meningococcal meningitis in familial deficiency of the fifth component of complement
107. Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease
108. Genetic influence on cytokine production and fatal meningococcal disease
109. Relation of a TNF gene polymorphism to severe sepsis in trauma patients
110. Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: A multicenter study
111. Factor V Leiden and other coagulation factor mutations affecting thrombotic risk
112. Effect of the Factor V Leiden mutation on the severity of meningococcal disease
113. The relationship between plasminogen activator inhibitor-I and proinflammatory and counterinflammatory mediators in children with meningococcal septic shock
114. Variation in plasminogen-activator-inhibitor-I gene and risk of meningococcal septic shock
115. Disseminated intravascular coagulation: Clinical spectrum and established as well as new diagnostic approaches
116. Current drug treatment strategies for disseminated intravascular coagulation
117. Disseminated intravascular coagulation
118. Disseminated intravascular coagulation: Clinical and laboratory aspects
119. Disseminated intravascular coagulation
120. Intercranial haemorrhage in idiopathic thrombocytopenic purpura. Paediatric haematology forum of the British society for haematology
121. Anti-endotoxin therapeutic options for the treatment of sepsis
122. Heparin 1986. Indications and effective use
123. Diagnosis and management of disseminated intravascular coagulation: The role of heparin therapy
124. Treatment of purpura fulminans in meningococcemia with protein C concentrate
125. Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans
126. Infectious purpura fulminans: Diagnosis and treatment
127. Infectious purpura fulminans: Caution needed in the use of protein C
128. Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation
129. Treatment of meningococcal disease in childhood
130. Deficiency of prostacyclin production in meningococcal shock
131. Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans
132. Treatment of fulminant meningococcemia with recombinant tissue plasminogen activator
133. Antithrombin replacement in patients with sepsis and septic shock
134. Antithrombin III replacement in animal models of acquired antithrombin III deficiency
135. Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons
136. Therapeutic use of antithrombin concentrate in sepsis
137. Antithrombin: Clinical experience in the DIC patient
138. Attenuation of tissue thrombosis and hemorrhage by ala-TFPI does not account for its protection against E. coli - A comparative study of treated and untreated non-surviving baboons challenged with LD100 E. coli
139. Tissue factor pathway inhibitor: Potential therapeutic applications
140. Early haemo-diafiltration in meningococcal septicaemia
141. Plasma exchange and haemodiafiltration in fulminant meningococcal sepsis
142. Peripheral gangrene associated with fulminating meningococcal septicaemia. Is early escharotomy indicated?